Synovus Financial Corp Bristol Myers Squibb CO Transaction History

Synovus Financial Corp

  • $7.52 Billion
  • Q2 2024

A detailed history of Synovus Financial Corp transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Synovus Financial Corp holds 259,359 shares of BMY stock, worth $13.8 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
259,359
Previous 266,876 2.82%
Holding current value
$13.8 Million
Previous $14.5 Million 25.57%
% of portfolio
0.14%
Previous 0.19%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
SELL
$40.25 - $52.99 $302,559 - $398,325
-7,517 Reduced 2.82%
259,359 $10.8 Million
Q1 2024

May 14, 2024
SELL
$47.98 - $54.4 $3.29 Million - $3.73 Million
-68,497 Reduced 20.42%
266,876 $14.5 Million
Q3 2023

Nov 13, 2023
BUY
$57.89 - $64.73 $183,221 - $204,870
3,165 Added 0.95%
335,373 $19.5 Million
Q2 2023

Aug 08, 2023
BUY
$63.71 - $70.74 $241,588 - $268,246
3,792 Added 1.15%
332,208 $21.2 Million
Q1 2023

May 11, 2023
SELL
$65.71 - $74.53 $1.54 Million - $1.75 Million
-23,450 Reduced 6.66%
328,416 $22.8 Million
Q4 2022

Feb 06, 2023
BUY
$68.48 - $81.09 $2.35 Million - $2.78 Million
34,246 Added 10.78%
351,866 $25.3 Million
Q3 2022

Oct 27, 2022
BUY
$0.13 - $76.84 $1,004 - $593,973
7,730 Added 2.49%
317,620 $22.6 Million
Q2 2022

Aug 10, 2022
BUY
$72.62 - $79.98 $2.12 Million - $2.33 Million
29,161 Added 10.39%
309,890 $23.9 Million
Q1 2022

May 12, 2022
SELL
$61.48 - $73.72 $1.11 Million - $1.34 Million
-18,127 Reduced 6.07%
280,729 $20.5 Million
Q4 2021

Feb 14, 2022
SELL
$53.63 - $62.52 $1.43 Million - $1.66 Million
-26,614 Reduced 8.18%
298,856 $18.6 Million
Q3 2021

Nov 08, 2021
BUY
$59.17 - $69.31 $3.06 Million - $3.59 Million
51,797 Added 18.93%
325,470 $19.3 Million
Q2 2021

Aug 11, 2021
BUY
$61.91 - $67.42 $129,763 - $141,312
2,096 Added 0.77%
273,673 $18.3 Million
Q1 2021

May 11, 2021
BUY
$59.34 - $66.74 $552,811 - $621,749
9,316 Added 3.55%
271,577 $17.1 Million
Q4 2020

Feb 11, 2021
BUY
$57.74 - $65.43 $500,086 - $566,689
8,661 Added 3.42%
262,261 $16.3 Million
Q3 2020

Nov 09, 2020
SELL
$57.43 - $63.64 $263,718 - $292,234
-4,592 Reduced 1.78%
253,600 $15.3 Million
Q2 2020

Aug 10, 2020
SELL
$54.82 - $64.09 $3.64 Million - $4.26 Million
-66,417 Reduced 20.46%
258,192 $15.2 Million
Q1 2020

Apr 24, 2020
BUY
$46.4 - $67.43 $3.84 Million - $5.57 Million
82,666 Added 34.17%
324,609 $18.1 Million
Q4 2019

Feb 06, 2020
BUY
$49.21 - $64.19 $1.04 Million - $1.36 Million
21,158 Added 9.58%
241,943 $15.5 Million
Q3 2019

Nov 01, 2019
BUY
$42.77 - $50.71 $619,309 - $734,280
14,480 Added 7.02%
220,785 $11.2 Million
Q2 2019

Aug 08, 2019
BUY
$44.62 - $49.34 $634,719 - $701,861
14,225 Added 7.41%
206,305 $9.37 Million
Q1 2019

May 09, 2019
BUY
$45.12 - $53.8 $2.49 Million - $2.97 Million
55,271 Added 40.4%
192,080 $9.18 Million
Q4 2018

Feb 07, 2019
SELL
$48.76 - $63.23 $367,991 - $477,196
-7,547 Reduced 5.23%
136,809 $7.11 Million
Q3 2018

Nov 01, 2018
BUY
$55.19 - $62.25 $57,894 - $65,300
1,049 Added 0.73%
144,356 $8.96 Million
Q2 2018

Aug 01, 2018
SELL
$50.53 - $62.98 $182,665 - $227,672
-3,615 Reduced 2.46%
143,307 $7.94 Million
Q1 2018

May 07, 2018
SELL
$59.92 - $68.98 $525,198 - $604,609
-8,765 Reduced 5.63%
146,922 $9.29 Million
Q4 2017

Feb 09, 2018
SELL
$59.94 - $65.35 $658,440 - $717,869
-10,985 Reduced 6.59%
155,687 $9.54 Million
Q3 2017

Nov 13, 2017
BUY
$55.23 - $63.74 $9.21 Million - $10.6 Million
166,672
166,672 $10.6 Million

Others Institutions Holding BMY

# of Institutions
2,428
Shares Held
1.5B
Call Options Held
29.7M
Put Options Held
32.2M
View Full List

About BRISTOL MYERS SQUIBB CO

BMY Quotes by TradingView
  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Synovus Financial Corp Portfolio

Follow Synovus Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Synovus Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Synovus Financial Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email